Authors: Kubodera, Noboru; Okano, Toshio; Nakagawa, Kimie; Ozono, Keiichi; Mikami, Koichi

Source: Current Pharmaceutical Design, Volume 6, Number 7, May 2000 , pp. 791-801(11)

Publisher: Bentham Science Publishers

Abstract:

Growing interests have been focused on the development of hybrid-analogs with modifications of the A-ring and the side chain of 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3). An exocyclic methylene group at C-10, a hydroxy group at C-1 and a hydroxy group at C-3 play a crucial role in the expression of biological activities of 1alpha,25(OH)2D3. However, relationship between the functional groups and activities has not been fully understood. We have synthesized and evaluated biological activities of several singly dehydroxylated A-ring analogs of 19-nor-1alpha,25(OH)2D3 and 19-nor-22-oxa-1alpha,25(OH)2D3. All of them have an extremely low binding affinity for vitamin D receptor (VDR). Some of them lack the 1alpha-hydroxy group that is considered to be essential for VDR-mediated gene expression, have greater or equivalent potencies to 1alpha,25(OH)2D3 for inducing differentiation and cell cycle G0-G1 arrest of human promyelocytic leukemia cells as well as for the transactivation of target genes including a rat 25-hydroxyvitamin D3-24-hydroxylase gene promoter and a human osteocalcin gene promoter in transfected mammalian cells. The assessment of a ligand/VDR/Retinoid X receptor complex formation using a two-hybrid luciferase assay revealed that the liganded VDR has high potency to form a heterodimer, but this could not explain the high biological potency of the 19-nor analogs. Other reason(s) including an interaction with transcriptional cofactors should be considered to explain the mechanism of action of 19-nor analogs.

Keywords: 19 Nor 1A 25 Dihydroxyvitamin D3; A Ring Analogs; Vitamin D; 19 Nor 1A 25 OH 2D3 Analogs; Transcriptional activity; 19 nor 1A 25 OH 2D3; 24 hydroxylase gene; osteocalcin gene; 19 nor 1A 25 OH 2D3 analogs; VDRE; electrophoretic mobility shift assay EMSA

Document Type: Research article

Affiliations: 1: Chugai Pharmaceutical Co., Ltd. 2-1-9 Kyobashi, Chuo-ku, Tokyo 104-8301, Japan

Publication date: 2000-05-01

More about this publication?

• Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.
  
  Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Kubodera, Noboru ;  Okano, Toshio ;  Nakagawa, Kimie ;  Ozono, Keiichi ;  Mikami, Koichi

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers